Physician profile
Robert H Stroud
NPI 1366486359
$5,329.04
in general payments reported to CMS, 2019-2025
21 companies · $828 in 2025
The $828 reported for 2025 was more than what 75% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $425 · 2020: $147 · 2021: $289 · 2022: $1,475 · 2023: $1,179 · 2024: $987 · 2025: $828.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,907 · Education: $86.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,906.87 |
| Education | $86.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $1,852.26 | 2022-2025 | Inspire |
| Acclarent, INC | $613.34 | 2019-2024 | Trudi Nav Cable, Relieva Spinplus |
| Genzyme Corporation | $592.62 | 2020-2025 | |
| Regeneron Healthcare Solutions, INC. | $554.56 | 2019-2025 | Dupixent |
| Glaxosmithkline, LLC. | $442.15 | 2021-2025 | Nucala |
| Stryker Corporation | $319.65 | 2019-2023 | Scopis Ent |
| Livanova USA, INC. | $137.71 | 2023 | Vns Therapy Sentiva Model 1000 Generator |
| Medtronic, INC. | $131.46 | 2022-2025 | Propel, Novapak, Pteye Parathyroid Detection System |
| Cochlear Americas | $126.24 | 2022-2024 | Baha, Cochlear Nucleus Ci632 Cochlear Implant With Slim Modiolar Electrode, Osia Osi300 Implant |
| Amgen INC. | $96.69 | 2025 | Tezspire |
| Sanofi-Aventis U.S. LLC | $96.59 | 2020-2024 | |
| Optinose US, INC. | $81.82 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $50.16 | 2025 | |
| Olympus America INC. | $45.75 | 2023 | Olympus |
| Aerin Medical INC. | $41.89 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Itamar Medical INC | $34.86 | 2021 | |
| Merck Sharp & Dohme LLC | $28.87 | 2021-2023 | |
| Paratek Pharmaceuticals, INC. | $22.47 | 2025 | Xhance |
| Merz Pharmaceuticals, LLC | $21.93 | 2023 | Xeomin |
| Smith+Nephew, INC. | $19.35 | 2023 | Halo |
| Phathom Pharmaceuticals, INC. | $18.67 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Stroud listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.